CALISTA THERAPEUTICS INC

Lincoln, RI · Biotech · Private

MT-002, a topical selective PI3K-Akt activator peptide for treating neurotrophic keratitis

Grants
$496K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
1 award · the Interior
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of a selective PI3K-Akt-activating neurotrophic small molecule drug, MT-002, for the healing of corneal wounds in Neurotrophic Keratitis.$247,998
Federal grantDepartment of Health and Human Services · Phase I · Development of a selective PI3K-Akt-activating neurotrophic small molecule drug, MT-002, for the healing of corneal wounds in Neurotrophic Keratitis.$247,998
Federal grant · SBIR/STTRFederal contract · USAspending

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1360PARAMITA THERAPEUTICS, INC.——
1361Abceutics——
1362Irex Pharma LLC——
1363CALISTA THERAPEUTICS INC——
1364DOOR PHARMACEUTICALS, LLC——
1365ADECTO PHARMACEUTICALS, INC.——
1366WEATHERWAX BIOTECHNOLOGIES CORPORATION——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.